Antigenix Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-24.
Antigenix Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 24, 2025. The filing reports $3.36M sold. Its industry group is Other Health Care. It names Christopher Whitfield (Chief Executive Officer), Shaun Hawkins (Director), Kwesi Frimpong-Boateng (Director) (SEC Form D, October 24, 2025).
Is this your company?
Sell to companies like Antigenix Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-24 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Antigenix Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Antigenix Therapeutics, Inc., from the filings we hold.
Other Health Care raises by companies based in New Jersey, filed in October 2025, largest first.
Get an email when Antigenix Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Antigenix Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Antigenix Therapeutics, Inc. →Get the full cited report on Antigenix Therapeutics, Inc.
What the filing shows about Antigenix Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Antigenix Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Antigenix Therapeutics, Inc.'s address as 300 Carnegie Center, Suite 150, Princeton, NJ 08540.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Antigenix Therapeutics, Inc. See pricing
Antigenix Therapeutics, Inc. is a registered filer with the SEC (CIK 2073993) and has filed since 2025-10-24. 1 filing is on record, the latest on 2025-10-24.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Antigenix Therapeutics, Inc.'s Form D of 2025-10-24 names Christopher Whitfield, Shaun Hawkins and Kwesi Frimpong-Boateng as its officers, directors or promoters.
Its new offerings report $3.36M sold across 1 offering, as its own filings state.
Trailing twelve months. 871 filings in Other Health Care, totalled by week.
On the filing as: Executive Officer, Director.
Christopher Whitfield is named as Chief Executive Officer on the Form D that Antigenix Therapeutics, Inc. filed with the SEC on 24 October 2025, one of 3 people that filing names.
Shaun Hawkins is named as Director on the Form D that Antigenix Therapeutics, Inc. filed with the SEC on 24 October 2025, one of 3 people that filing names.
Kwesi Frimpong-Boateng is named as Director on the Form D that Antigenix Therapeutics, Inc. filed with the SEC on 24 October 2025, one of 3 people that filing names.
3 people named on the filing — 1 holding an executive role and 2 as directors only.
Named as of the 2025-10-24 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Antigenix Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Antigenix Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Antigenix Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Antigenix Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Antigenix Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Antigenix Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Health care raises in Northern New Jersey
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/antigenix-therapeutics-inc-form-d-25000001